Source-grounded facts extracted from Monopar Therapeutics's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Monopar Therapeutics reported year ended December 31, 2025 results: net income Net loss for the year ended December 31, 2025, was $13.7 million, or $1.85 per share.
“Net loss for the year ended December 31, 2025, was $13.7 million, or $1.85 per share”
Monopar Therapeutics reported fourth quarter and full year ended December 31, 2025 results: net income Net loss for the fourth quarter of 2025 was $5.2 million, or $0.61 per share.
“the fourth quarter and full-year 2025 financial results”
Quan Vu was appointed as Chief Financial Officer at Monopar Therapeutics.
“On February 27, 2025, the Company’s Board of Directors appointed Quan Vu, age 53, to succeed Mr. Radhakrishnan as Monopar’s Chief Financial Officer, principal accounting officer and principal financial officer effective March 3, 2025.”
Karthik Radhakrishnan was terminated as Chief Financial Officer at Monopar Therapeutics.
“On February 28, 2025, Karthik Radhakrishnan’s employment with Monopar Therapeutics Inc. (the “Company” or “Monopar”) terminated.”
Lavina Talukdar was appointed as Director at Monopar Therapeutics.
“On February 21, 2025, the Company’s Board appointed Lavina Talukdar to the Board.”
Michael J. Brown resigned as Director at Monopar Therapeutics.
“Michael J. Brown has resigned from his position as a member of the Monopar Therapeutics Inc. (the” Company”) Board of Directors (the “Board”) effective February 19, 2025.”
Karthik Radhakrishnan was appointed as Chief Financial Officer at Monopar Therapeutics.
“On May 23, 2024, the Company’s Board of Directors appointed, Karthik Radhakrishnan, age 53, to succeed Ms. Tsuchimoto as Monopar’s Chief Financial Officer, principal accounting officer and principal financial officer effective July 1, 2024.”
Kim R. Tsuchimoto departed as Chief Financial Officer at Monopar Therapeutics.
“Effective June 30, 2024, after a career spanning more than 35 years, Kim R. Tsuchimoto, the Chief Financial Officer of Monopar Therapeutics Inc. (“Monopar” or the “Company”), will be retiring.”
Monopar Therapeutics reported first quarter ended March 31, 2024 results: net income $1.6 million, EPS $0.10 per share.
“Net loss for the first quarter of 2024 was $1.6 million or $0.10 per share compared to net loss of $2.4 million or $0.19 per share for the first quarter of 2023.”
Monopar Therapeutics reported fourth quarter and full year ended December 31, 2023 results: net income Net loss for the fourth quarter of 2023 was $1.8 million or $0.12 per share compared to $2.9 million or $0.22 per share.
“Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.